Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Test Anal ; 15(11-12): 1356-1360, 2023.
Article in English | MEDLINE | ID: mdl-36929692

ABSTRACT

19-Norandrosterone (19NA) is the preferred urinary target compound to identify doping with nandrolone or related 19-norsteroids. At concentrations between 2.5 and 15 ng/mL, isotope ratio mass spectrometry (IRMS) is required to establish exogenous origin of urinary 19NA. An absolute difference of 3‰ between urinary 19NA and an endogenous reference compound (ERC) constitutes a finding for exogenous origin of 19NA. Over the last 3 years, 77 samples containing urinary 19NA between 2.5 and 15 ng/mL were analyzed at our laboratory. The measured δ13 C values for 19NA ranged from -29.5‰ to -16.8‰. In comparison, the δ13 C values for the corresponding urinary ERCs ranged from -22.4‰ to -16.2‰. Due to the considerable overlap in values between the target compound and the natural range of urinary ERCs, it can be challenging to distinguish between endogenous and exogenous origins of urinary 19NA. In addition, it is well known that consumption of offal from non-castrated pigs can produce 19NA in urine. To determine whether this could cause a positive IRMS finding under the current IRMS positivity criteria, meat from non-castrated boars fed a mixture of corn and soy was consumed by 13 volunteers. Two volunteers produced 19NA findings above 2.5 ng/mL, and the measured isotope values, while inconsistent with documented 19-norsteroid preparations, did meet IRMS positivity criteria. However, these increases in 19NA urinary concentrations were short-lived due to rapid elimination. Timely follow-up collections may help support a claim for dietary exposure when low urinary concentrations of 19NA with pseudo-endogenous isotope values are observed.


Subject(s)
Estranes , Meat , Swine , Male , Humans , Animals , Gas Chromatography-Mass Spectrometry/methods , Estranes/analysis , Carbon Isotopes/analysis , Meat/analysis
2.
Drug Test Anal ; 12(11-12): 1554-1560, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32697436

ABSTRACT

Identification and evaluation of long-term markers is crucial in prolonging the detection window for anabolic steroid abuse in sport. Recently, sulfoconjugated epiandrosterone was identified as a potential long-term marker for the abuse of certain endogenous anabolic agents, including testosterone, which continues to be widely used as a performance enhancing agent in sport. To evaluate the applicability of epiandrosterone sulfate as a marker for testosterone use, administration studies were conducted with multiple modes of testosterone administration - transdermal, intramuscular, and subcutaneous. A modified sample preparation method was used to collect both glucuronidated and sulfoconjugated analytes of interest. Carbon isotope ratio measurements from the administration studies are presented here. Epiandrosterone was less effective than the conventionally used target compounds for detection of the low dose application (transdermal gel). With intramuscular administration, epiandrosterone was more diagnostic than with transdermal administration, but it did not prolong the detection window more than the conventional target compounds. With subcutaneous administration, the doses administered to the subjects were varied and the effect on the epiandrosterone values was dependent on the magnitude of the dose administered. Epiandrosterone does not appear to be a useful marker in the detection of low dose testosterone administration. It is responsive to higher dose administration, but it does not provide an extension of the detection window relative to conventional target compounds.


Subject(s)
Anabolic Agents/administration & dosage , Anabolic Agents/metabolism , Androsterone/metabolism , Substance Abuse Detection/standards , Testosterone/administration & dosage , Testosterone/metabolism , Administration, Cutaneous , Adult , Anabolic Agents/analysis , Androsterone/analysis , Biomarkers/metabolism , Doping in Sports/methods , Doping in Sports/prevention & control , Gas Chromatography-Mass Spectrometry/methods , Gas Chromatography-Mass Spectrometry/standards , Gels , Humans , Injections, Intramuscular , Injections, Subcutaneous , Intramuscular Absorption/drug effects , Intramuscular Absorption/physiology , Male , Skin Absorption/drug effects , Skin Absorption/physiology , Subcutaneous Absorption/drug effects , Subcutaneous Absorption/physiology , Substance Abuse Detection/methods , Testosterone/analysis
3.
Eur J Nucl Med Mol Imaging ; 45(6): 898-903, 2018 06.
Article in English | MEDLINE | ID: mdl-29396636

ABSTRACT

PURPOSE: Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvß3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. METHODS: The study group comprised 17 men with bone-predominant metastatic PCa who underwent whole-body planar and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging with 99mTc-maraciclatide before (n = 17) and 12 weeks after (n = 11) starting treatment with abiraterone. Tumour to normal bone (T:N) ratios, tumour to muscle (T:M) ratios and CT Hounsfield units (HU) were measured in up to five target metastases in each subject. An oncologist blinded to study scans assessed clinical responses up to 24 weeks using conventional criteria. RESULTS: Before treatment, metastases showed specific 99mTc-maraciclatide accumulation (mean planar T:N and T:M ratios 1.43 and 3.06; SPECT T:N and T:M ratios 3.1 and 5.19, respectively). Baseline sclerotic lesions (389-740 HU) showed lower T:M ratios (4.22 vs. 7.04, p = 0.02) than less sclerotic/lytic lesions (46-381 HU). Patients with progressive disease (PD; n = 5) showed increased planar T:N and T:M ratios (0.29 and 12.1%, respectively) and SPECT T:N and T:M ratios (11.9 and 20.2%, respectively). Patients without progression showed decreased planar T:N and T:M ratios (0.27 and -8.0%, p = 1.0 and 0.044, respectively) and SPECT T:N and T:M ratios (-21.9, and -27.2%, p = 0.3 and 0.036, respectively). The percentage change in CT HU was inversely correlated with the percentage change in SPECT T:M ratios (r = -0.59, p = 0.006). CONCLUSIONS: 99mTc-maraciclatide accumulates in PCa bone metastases in keeping with increased αvß3 integrin expression. Greater activity in metastases with lower CT density suggests that uptake is related to osteoclast activity. Changes in planar and SPECT T:M ratios after 12 weeks of treatment differed between patients with and without PD and 99mTc-maraciclatide imaging may be a potential method for assessing early response.


Subject(s)
Bone Neoplasms/metabolism , Integrin alphaVbeta3/metabolism , Tomography, Emission-Computed, Single-Photon , Aged , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Humans , Male , Radionuclide Imaging , Radiopharmaceuticals , Tomography, X-Ray Computed
4.
Nucl Med Biol ; 40(6): 788-94, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23701702

ABSTRACT

INTRODUCTION: The αvß3 integrin, which is expressed by angiogenic epithelium and some tumor cells, is an attractive target for the development of both imaging agents and therapeutics. While optimal implementation of αvß3-targeted therapeutics will require a priori identification of the presence of the target, the clinical evaluation of these compounds has typically not included parallel studies with αvß3-targeted diagnostics. This is at least partly due to the relatively limited availability of PET radiopharmaceuticals in comparison to those labeled with (99m)Tc. In an effort to begin to address this limitation, we evaluated the tumor uptake of (99m)Tc-NC100692, a cyclic RGD peptide that binds to αvß3 with ~1-nM affinity, in an αvß3-positive tumor model as well as its in vivo specificity. METHODS: MicroSPECT imaging was used to assess the ability of cilengitide, a therapeutic with high affinity for αvß3, to block and displace (99m)Tc-NC100692 in an orthotopic U87 glioma tumor. The specificity of (99m)Tc-NC100692 was quantitatively evaluated in mice bearing subcutaneous U87MG tumors, by comparison of the biodistribution of (99m)Tc-NC100692 with that of the non-specific structural analogue (99m)Tc-AH-111744 and by blocking uptake of (99m)Tc-NC100692 with excess unlabeled NC100692. RESULTS: MicroSPECT imaging studies demonstrated that uptake of (99m)Tc-NC100692 in the intracranial tumor model was both blocked and displaced by the αvß3-targeted therapeutic cilengitide. Biodistribution studies provided quantitative confirmation of these imaging results. Tumor uptake of (99m)Tc-NC100692 at 1h post-injection was 2.8 ± 0.7% ID/g compared to 0.38 ± 0.1% ID/g for (99m)Tc-AH-111744 (p < 0.001). Blocking (99m)Tc-NC100692 uptake by pre-injecting the mice with excess unlabeled NC100692 reduced tumor uptake by approximately five-fold, to 0.68 ± 0.3% ID/g (p = 0.01). CONCLUSION: These results confirm that (99m)Tc-NC100692 does, in fact, target the αvß3 integrin and may, therefore, be useful in identifying patients prior to anti-αvß3 therapy as well as monitoring the response of these patients to therapy.


Subject(s)
Glioma/diagnostic imaging , Glioma/metabolism , Integrin alphaVbeta3/metabolism , Organotechnetium Compounds/metabolism , Peptides, Cyclic/metabolism , Tomography, Emission-Computed, Single-Photon/methods , Animals , Biological Transport , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Glioma/blood supply , Glioma/pathology , Humans , Mice , Neovascularization, Pathologic/diagnostic imaging , Organotechnetium Compounds/pharmacokinetics , Peptides, Cyclic/pharmacokinetics
5.
Mol Imaging Biol ; 14(6): 725-34, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22371188

ABSTRACT

PURPOSE: A novel molecular imaging agent has been developed recently, which stains tissues of low extracellular pH [pH (low) insertion peptide, pHLIP(®)]. A pH-dependent process of peptide folding and insertion into cell membranes has been found in vitro. Targeting of acidic solid tumours has been demonstrated in vivo using fluorescence and PET labels. Here, we present proof of feasibility studies of pHLIP with a single-photon emission computed tomography (SPECT) label, (99m)Tc-AH114567, with focus on preclinical efficacy and imageability. PROCEDURES: Lewis lung carcinoma, lymph node carcinoma of the prostate and prostate adenocarcinoma tumour xenografts were grown in mice and characterised by the angiogenesis marker (99m)Tc-NC100692 and by extracellular pH measurements with (31)P-MRS of 3-aminopropyl phosphonate. Biodistribution was assessed and CT/SPECT imaging performed. Oral administration of bicarbonate served as control. RESULTS AND CONCLUSION: Tc-AH114567 can be obtained via a robust synthesis with good radiolabelling profile and improved formulation. The tracer retains the pH-dependent ability to insert into membranes and to target tumours with similar pharmacokinetics and efficacy that had been demonstrated earlier for pHLIP with optical or (64)Cu PET labels. Despite the inherent challenges of SPECT compared to optical and PET imaging, e.g., in terms of lower sensitivity, (99m)Tc-AH114567 shows adequate image quality and contrast. The main development need for transitioning SPECT labelled pHLIP into the clinic is more rapid background signal reduction, which will be the focus of a subsequent optimisation study.


Subject(s)
Diagnostic Imaging/methods , Membrane Proteins , Technetium , Amino Acid Sequence , Animals , Hydrogen-Ion Concentration , Kidney/metabolism , Liver/metabolism , Male , Membrane Proteins/chemistry , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Neoplasms/diagnostic imaging , Neoplasms/pathology , Peptides, Cyclic/pharmacokinetics , Rats , Technetium/pharmacokinetics , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed
6.
J Nucl Med ; 52(3): 424-30, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21321268

ABSTRACT

UNLABELLED: Arginine-glycine-aspartate (RGD)-binding α(V)ß(3)-integrin and α(V)ß(5)-integrin play key roles in tumor angiogenesis. We examined an (18)F-labeled small peptide (fluciclatide [United States Adopted Name (ASAN)-approved, International Nonproprietary Name (INN)-proposed name], previously referred to as AH111585) containing an RGD sequence. Fluciclatide binds with a high (nM) affinity to α(V)ß(3)-integrin and α(V)ß(5)-integrin, which are highly expressed on tumors and the tumor neovasculature. In this study, (18)F-fluciclatide was used to examine the response of human glioblastoma xenografts to treatment with the antiangiogenic agent sunitinib. METHODS: U87-MG tumor uptake of (18)F-fluciclatide was determined by small-animal PET after longitudinal administration of the antiangiogenic agent sunitinib (a 2-wk dosing regimen). Tumor sizes were measured throughout the study, and tumor volumes were calculated. Tumor microvessel density (MVD) after therapy was also analyzed. RESULTS: Dynamic small-animal PET of (18)F-fluciclatide uptake after administration of the clinically relevant antiangiogenic agent sunitinib revealed a reduction in the tumor uptake of (18)F-fluciclatide compared with that in vehicle-treated controls over the 2-wk dosing regimen. Skeletal muscle, used as a reference tissue, showed equivalent (18)F-fluciclatide uptake in both therapy and control groups. A reduction in tumor MVD was also observed after treatment with the antiangiogenic agent. No significant changes in tumor volume were observed in the 2 groups. CONCLUSION: The data demonstrated that (18)F-fluciclatide detected changes in tumor uptake after acute antiangiogenic therapy markedly earlier than any significant volumetric changes were observable. These results suggest that this imaging agent may provide clinically important information for guiding patient care and monitoring the response to antiangiogenic therapy.


Subject(s)
Glioblastoma/drug therapy , Glioblastoma/metabolism , Indoles/therapeutic use , Integrin alphaVbeta3/metabolism , Peptides/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , Pyrroles/therapeutic use , Receptors, Vitronectin/metabolism , Angiogenesis Inhibitors/therapeutic use , Animals , Cell Line, Tumor , Glioblastoma/diagnostic imaging , Humans , Male , Mice , Mice, Nude , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Reproducibility of Results , Sensitivity and Specificity , Sunitinib
7.
Lab Anim (NY) ; 39(10): 313-7, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20859279

ABSTRACT

Researchers have used the rat model of myocardial infarction for more than 20 y to successfully mimic the detrimental effects of coronary occlusion of the left anterior descending (LAD) coronary artery in humans. But researchers have published little about this surgery's intricacies or about the pathological progression of the disease after surgery. The authors describe a refined technique that uses a suture anchor at the apex of the heart, which allows easy and accurate placement of a ligature around the LAD. Furthermore, they detail the pathological timeline for the deposition of collagen in the injured left ventricle, a hallmark of myocardial infarction. Researchers can use this refined technique to easily create a rat myocardial infarction and use the pathophysiological markers described herein to follow disease progression.


Subject(s)
Cardiovascular Surgical Procedures/methods , Myocardial Infarction/surgery , Animals , Cardiovascular Surgical Procedures/instrumentation , Collagen/metabolism , Female , Heart Ventricles/pathology , Myocardial Infarction/pathology , Rats , Rats, Wistar , Sutures
8.
J Nucl Med ; 50(1): 116-22, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19091899

ABSTRACT

UNLABELLED: Despite the recent development of various radiolabeled Arg-Gly-Asp (RGD) peptides for imaging the alphavbeta3 integrin receptor, relatively little attention has been focused on the ability of these radiotracers to monitor changes in tumor vascularity after antitumor therapies. This study describes the favorable in vivo kinetics and tumor-targeting properties of 18F-AH111585, a novel 18F-RGD peptide, and its ability to monitor tumor vascularity noninvasively. METHODS: Mice bearing Lewis lung carcinoma (LLC) tumors or Calu-6 non-small cell lung tumor xenografts were used for in vivo biodistribution and small-animal PET imaging studies. In addition, some animals were treated with either low-dose paclitaxel or the vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD4190. Tumor uptake of 18F-AH111585 and microvessel density were then assessed. RESULTS: Biodistribution of 18F-AH111585 demonstrated rapid clearance from the blood and key background organs and good tumor accumulation, with 1.5 percentage injected dose per gram (%ID/g) present at 2 h after injection in LLC tumors. Small-animal PET imaging of Calu-6 tumors allowed visualization of tumors above background tissue, with mean baseline uptake of 2.2 %ID/g. Paclitaxel therapy reduced the microvessel density in LLC tumor-bearing mice and resulted in significantly reduced 18F-AH111585 tumor uptake (P<0.05). ZD4190 therapy resulted in a significant (31.8%) decrease in 18F-AH111585 uptake in Calu-6 tumors, compared with the vehicle control-treated Calu-6 tumors, which had a 26.9% increase in 18F-AH111585 uptake over the same period (P<0.01). CONCLUSION: 18F-AH111585 is a promising 18F-labeled RGD tracer that offers a new approach to noninvasively image tumor vasculature. This tracer may reveal important information in the assessment of the impact of antitumor therapies, in particular those that predominantly target tumor blood vessels.


Subject(s)
Antineoplastic Agents/therapeutic use , Neoplasms/blood supply , Neoplasms/drug therapy , Oligopeptides , Peptides , Polyethylene Glycols , Animals , Antineoplastic Agents/pharmacology , Carcinoma, Lewis Lung/blood supply , Carcinoma, Lewis Lung/diagnostic imaging , Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/metabolism , Carcinoma, Non-Small-Cell Lung/blood supply , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/metabolism , Dose-Response Relationship, Drug , Mice , Neoplasms/diagnostic imaging , Neoplasms/metabolism , Oligopeptides/pharmacokinetics , Paclitaxel/pharmacology , Paclitaxel/therapeutic use , Peptides/pharmacokinetics , Polyethylene Glycols/pharmacokinetics , Positron-Emission Tomography , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use , Protein-Tyrosine Kinases/antagonists & inhibitors , Quinazolines/pharmacology , Quinazolines/therapeutic use , Receptors, Vascular Endothelial Growth Factor/metabolism , Tissue Distribution/drug effects , Triazoles/pharmacology , Triazoles/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...